Facility-Level Average BZD Use at the Start of PDSI Phase 2 and Expected Quarterly Change Among a Cohort of Long-Term BZD Users, Overall and By Facility Priority Status
| Overall (N = 140) | Priority (n = 47) | Nonpriority (n = 93) | |
|---|---|---|---|
| Facility-level daily dose of benzodiazepines, mean (SD)a,b | |||
| At the start of PDSI Phase 2 | 1.34 (0.17) | 1.35 (0.14) | 1.34 (0.19) |
| Average yearly change | –0.27 (0.09) | –0.29 (0.09) | –0.26 (0.09) |
BZD = benzodiazepine; PDSI = Psychotropic Drug Safety Initiative.
↵a From a model in which the outcome was facility-level average daily dose of BZDs and included terms for PDSI phase 2 status (0 or 1), time (quarter, 0-6), their interaction, facility-level average age, and facility-level random intercepts and slopes. Fixed and random effects were used to estimate the expected facility-level starting dose and change over time (slope) for each facility, with average age set to the mean.
↵b In oral lorazepam-equivalent mg.